Outpatient Oncology Infusion Market Size, Share and Industry Analysis Report by Product (Infusion Pumps, Intravenous Sets, IV Cannulas, Needleless Connectors), Application (Lung Cancer, Liver Cancer, Breast Cancer, Prostate Cancer), By Therapy (Chemothera

Outpatient Oncology Infusion Market Size, Share and Industry Analysis Report by Product (Infusion Pumps, Intravenous Sets, IV Cannulas, Needleless Connectors), Application (Lung Cancer, Liver Cancer, Breast Cancer, Prostate Cancer), By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy) and Mode (Intramuscular (IM), Intravenous (IV), Subcutaneous), Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2022- 2030

The global outpatient oncology infusion market is expected to register commendable growth by 2030, due in part to the rising prevalence of cancer cases and growing investment interest towards R&D for cancer treatment worldwide.

Outpatient oncology infusion therapy is rapidly emerging as a major component of modern cancer treatment protocols. Infusion therapy refers to procedures where medicine is administered directly into the bloodstream of the patient to shrink or curb the growth of cancer cells.

Outpatient infusion therapies for cancer treatment encompass various services, including hormone therapy, immunotherapy, chemotherapy, and blood transfusions, as well as other infusion treatments the patient may require, like antibiotics, pain medication, and hydration fluids.

The global outpatient oncology infusion market is bifurcated in terms of product, application, therapy, mode, and region.

With respect to product, the outpatient oncology infusion industry is further classified into intravenous sets, infusion pumps, needleless connectors, and IV cannulas.

Of these, the IV cannulas segment registered revenues worth nearly $4 billion in 2021. This was credited largely to a rising adoption of IV cannulas for the infusion of medication or collection of blood samples in investigational medical processes.

Based on application, the outpatient oncology infusion market is segregated into liver cancer, lung cancer, prostate cancer, breast cancer, and others.

The liver cancer segment held a 3.9% share of the overall market in 2021, given the rapid rise in the prevalence of liver cancer, as well as the escalating demand for infusion therapies like targeted therapy or immunotherapy.

In February 2022, for instance, oncologists and surgeons at Penn Medicine’s Department of Surgery used adjuvant hepatic artery infusion chemotherapy along with systemic chemotherapy, in order to treat unresectable CLMs (colorectal liver metastases) or mitigate the risk of recurrence among individuals with resected CLMs.

From a therapy perspective, the outpatient oncology infusion industry is categorized into targeted therapy, immunotherapy, chemotherapy, and hormonal therapy. The hormonal therapy segment recorded a remuneration of over $6 billion in 2021, driven by the growing prevalence of cancer across the globe.

Additionally, rising awareness among patients and physicians regarding the benefits of alternative cancer treatments like hormone therapy is a major driver propelling industry growth.

With regard to mode, the overall outpatient oncology infusion market is divided into Intravenous (IV), Intramuscular (IM), Subcutaneous, and other.

In 2021, the intravenous (IV) segment accounted for almost 30.6% of the overall market share due to the rising occurrence of lung cancer, wherein IV solutions act as the primary source of energy for the patients. In addition, increasing rollout of intravenous (IV) products has also elevated the industry outlook.

In March 2022, for instance, a new therapy was approved by the FDA for the treatment of advanced prostate cancer metastasizing within the body. Known as Pluvicto, the therapy was designed to be administered via intravenous infusion, to identify and destroy tumors too small to be noticed through conventional medical imaging techniques.

On the regional front, the Latin America outpatient oncology infusion industry is poised to register a 12.2% CAGR through the forecast time period. This growth is mainly credited to technological advancements in the regional medical domain, and strong market players focus on developing novel and sophisticated outpatient oncology infusion therapies.